Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $38.57.

A number of research firms have issued reports on ZNTL. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Wedbush upped their price target on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $12.71 on Thursday. Zentalis Pharmaceuticals has a 1 year low of $9.56 and a 1 year high of $31.46. The stock’s 50 day simple moving average is $14.04 and its 200 day simple moving average is $14.19. The firm has a market cap of $901.90 million, a price-to-earnings ratio of -2.80 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.09. As a group, sell-side analysts anticipate that Zentalis Pharmaceuticals will post -3.72 EPS for the current year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the transaction, the chief financial officer now owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Ameritas Investment Partners Inc. increased its stake in shares of Zentalis Pharmaceuticals by 10.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,057 shares of the company’s stock worth $114,000 after acquiring an additional 376 shares in the last quarter. US Bancorp DE increased its stake in shares of Zentalis Pharmaceuticals by 88.7% during the second quarter. US Bancorp DE now owns 887 shares of the company’s stock valued at $25,000 after purchasing an additional 417 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Zentalis Pharmaceuticals by 22.9% during the second quarter. Royal Bank of Canada now owns 3,296 shares of the company’s stock valued at $93,000 after purchasing an additional 615 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of Zentalis Pharmaceuticals by 15,160.0% in the 1st quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock worth $35,000 after purchasing an additional 758 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Zentalis Pharmaceuticals by 1.6% in the 3rd quarter. Legal & General Group Plc now owns 55,763 shares of the company’s stock worth $1,119,000 after buying an additional 854 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.